Clinical Trial Update: Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating tislelizumab in combination with thoracic radiotherapy as neoadjuvant therapy for resectable non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Northern Jiangsu People's Hospital | Conditions: Resectable NSCLC | Phase 2 | Status: RECRUITING